# Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-08-19 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-injection-site-reactions

> Semaglutide produced injection site reactions in 1.4% against 1% on placebo. Tirzepatide runs 6–8% against 2%. If you react on one and not the other, that is not your technique.

## Key points

- Semaglutide: 1.4% against 1% on placebo, close to background.
- Tirzepatide: 6%, 8%, 8% across 5, 10 and 15 mg against 2%, a fourfold gap between the drugs.
- Reactions plateau after the first dose step rather than climbing.
- Anaphylaxis and angioedema are a separate matter, and a prior serious reaction is a contraindication.

These two drugs are not the same on this, and the gap is larger than almost anything else separating them. Semaglutide produced injection site reactions in **1.4%** of patients against 1% on placebo, barely a difference.[1] Tirzepatide runs **6% to 8%** against 2%, rising with dose.[2] If you are getting lumps and redness on one and did not on the other, that is not your technique.

## The two drugs, side by side

*Injection site reactions and hypersensitivity, from each label's adverse reactions table.*

|   | Placebo | Drug |
| --- | --- | --- |
| Semaglutide 2.4 mg — injection site reactions[1] | 1% | 1.4% |
| Tirzepatide — injection site reactions, 5/10/15 mg[2] | 2% | **6% / 8% / 8%** |
| Tirzepatide — hypersensitivity reactions[2] | 3% | 5% / 5% / 5% |

The semaglutide label lists what counts as a reaction: itching, redness, inflammation, hardening of the tissue, and irritation.[1] Those are local, they settle, and at 1.4% against 1% they are close to background.

Tirzepatide’s figures behave differently. They roughly triple from placebo at the lowest dose and then flatten (6%, 8%, 8%), the same plateau pattern its [gastrointestinal effects](https://glpwatchdog.org/research/glp1-burping-reflux-and-gas) show. Getting through the first dose tends to predict the rest.

## The serious reaction is a different thing entirely

A lump at the injection site and an allergic reaction to the drug are not two points on one scale. Conflating them is how people either panic about [a bruise](https://glpwatchdog.org/research/qna/top-injection-site-questions-reddit-answered) or ignore something that matters.

The semaglutide label carries serious hypersensitivity in its warnings: anaphylaxis and angioedema have been reported. If one occurs, the instruction is to stop the drug, treat promptly, and monitor until it resolves. The drug then becomes **contraindicated**, both for the molecule and for any of the excipients in it.[1]

> A prior serious reaction is not a caution to weigh. It is a contraindication.

> **What to act on immediately.** Swelling of the face, lips, tongue or throat; difficulty breathing or swallowing; a widespread rash or hives; faintness. That is anaphylaxis or angioedema, not an injection site reaction, and it is emergency care rather than a call to the prescriber. Tell them afterward too, because it changes whether you can ever take this drug again. What happens after a reaction, including whether another GLP-1 is an option, is in [GLP-1 allergic reactions and anaphylaxis](https://glpwatchdog.org/research/glp1-allergic-reactions-and-anaphylaxis).

## What is ordinary

- **A small red mark or mild itch for a day or two.** Common with any subcutaneous injection, and on the label for both drugs.
- **A firm lump under the skin** (induration, in the label’s language). This is why every label asks for site rotation with each dose. Our [rotation calendar](https://glpwatchdog.org/tools/glp1-injection-site-rotation-calendar) tracks it, and [where to inject](https://glpwatchdog.org/research/where-to-inject-glp1) covers technique.
- **A small bruise**, which is about the needle and the capillary it happened to meet, not the drug.

None of that needs treating. [Rotating sites](https://glpwatchdog.org/research/cheat-sheets/glp1-injection-site-rotation-cheat-sheet) is the one thing that reliably helps, and the label asks for it precisely because repeatedly injecting the same spot is what produces persistent lumps. Itching or a rash that spreads beyond the injection site, or skin that hurts all over, is a different reaction, covered in [GLP-1 skin sensitivity, rash and itching](https://glpwatchdog.org/research/glp1-skin-sensitivity-rash-and-itching).

## If reactions are why you want to switch

That is a legitimate reason, and the numbers support it in one direction: someone reacting on tirzepatide has a reasonable expectation of fewer local reactions on semaglutide, because 1.4% against 1% is close to nothing. The reverse is not true.

Weigh that against everything else that differs between them: effect size, cost, coverage and the other side effects. Our [tirzepatide timeline](https://glpwatchdog.org/research/tirzepatide-results-timeline) and [semaglutide timeline](https://glpwatchdog.org/research/semaglutide-results-timeline) set out what each does on the scale, and switching itself has a dose-equivalence problem covered by the [switch calculator](https://glpwatchdog.org/tools/brand-switch-dose-equivalence-calculator). A sore spot where you inject is also a different thing from aches elsewhere in the body, which [the trials counted separately](https://glpwatchdog.org/research/glp1-joint-pain-back-pain-and-aches).

Those label figures describe the approved drugs. A compounded vial is a different preparation, and some carry added ingredients: [EllieMD](https://glpwatchdog.org/reviews/elliemd) sells compounded semaglutide and tirzepatide injections with B12, L-carnitine or glycine, and [Nuform Health](https://glpwatchdog.org/reviews/nuform-health) sells both as vitamin blends. Because the label’s contraindication reaches the excipients as well as the molecule, ask for the full ingredient list of whatever you inject. [Independent Wellness](https://glpwatchdog.org/reviews/independent-wellness) names its three partner pharmacies, which gives that question somewhere to go.

If a switch between molecules is on the table, it is simpler when one prescriber can make it. [Lemonaid Health](https://glpwatchdog.org/reviews/lemonaid-health) prescribes compounded semaglutide and tirzepatide as well as brand Zepbound, Wegovy and Ozempic, and [Noom Med](https://glpwatchdog.org/reviews/noom-med) offers compounded microdoses of either drug beside brand Wegovy and Zepbound. [Factor Health MD](https://glpwatchdog.org/reviews/factor-health-md) lists compounded liraglutide next to semaglutide and tirzepatide, and every patient there has a video visit with a provider. Check the cost side as well: [Coby Health](https://glpwatchdog.org/reviews/coby-health) and [Boston Medical Group](https://glpwatchdog.org/reviews/boston-medical-group) price compounded semaglutide by dose, so a dose change moves the bill.

[Embody](https://glpwatchdog.org/reviews/embody) works the other way: a month of its compounded semaglutide injection costs the same at every dose, and it names RedRock Pharmacy among the pharmacies that fill its prescriptions.

## Frequently asked questions

### Are injection site reactions normal on a GLP-1?

It depends which one. On semaglutide they are close to background: 1.4% against 1% on placebo. On tirzepatide they run 6% to 8% against 2%, rising with dose. Redness, itching, inflammation, hardening and irritation are what the label counts.

### Why do I react to tirzepatide and not semaglutide?

Because the drugs differ here, and by more than almost anything else separating them. It is not your technique. Tirzepatide's rate is several times semaglutide's in each label's own trials.

### Does it get worse at higher doses?

Not much after the first step. Tirzepatide's figures run 6%, 8%, 8% across 5, 10 and 15 mg, a jump from placebo to the lowest dose followed by a plateau. Tolerating the first dose largely predicts the rest.

### When is a reaction an emergency?

The emergency signs are listed in the warning above. They point to an allergic reaction affecting the airway or the whole body, rather than the skin around the injection. That is emergency care, not a call to the prescriber. It also matters afterward, because a serious reaction makes the drug contraindicated rather than merely risky.

### What actually helps with lumps?

Rotating sites with each dose, which every label asks for. Persistent hardening comes from repeatedly injecting the same spot, and no cream addresses that.

## References

1. Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information: injection site reactions 1.4% vs 1%, and Hypersensitivity Reactions including anaphylaxis and angioedema (revised 06/2026). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Section 6.1 Adverse Reactions, dose-stratified table (SPL effective 2026-04-22). DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

---

Cite as: GLP Watchdog, Ruth Calder, "Injection Site Reactions: Where Semaglutide and Tirzepatide Really Differ", published 2026-08-19, updated 2026-10-27. https://glpwatchdog.org/research/glp1-injection-site-reactions

Canonical HTML page: https://glpwatchdog.org/research/glp1-injection-site-reactions

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
